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Abstract
Cancer stem-like cells represent a population of tumour-initiating cells that lead to the relapse and metastasis of cancer. Conventional anti-
cancer therapeutic drugs are usually ineffective in eliminating the cancer stem-like cells. Therefore, new drugs or therapeutic methods
effectively targeting cancer stem-like cells are in urgent need to successfully cure cancer. Gamboge is a natural anti-cancer medicine whose
pharmacological effects are different from those of conventional chemotherapeutical drugs and they can kill some kinds of cancer cells selec-
tively. In this study, we identified a new gamboge derivative, Compound 2 (C2), which presents eminent suppression effects on cancer cells.
Interestingly, when compared with cisplatin (CDDP), C2 effectively suppresses the growth of both cancer stem-like cells and non-cancer stem-
like cells derived from head and neck squamous cell carcinoma (HNSCC), inhibiting the formation of tumour spheres and colony in vitro, result-
ing in the loss of expression of multiple cancer stem cell (CSC)-related molecules in HNSCC. Treating with C2 effectively inhibited the growth of
HNSCC in BALB/C nude mice. Further investigation found that C2 notably inhibits the activation of epithelial growth factor receptor and the
phosphorylation of its downstream protein kinase homo sapiens v-akt murine thymoma viral oncogene homolog (AKT) in HNSCC, resulting in
down-regulation of multiple CSC-related molecules in HNSCC. Our study has demonstrated that C2 effectively inhibits the stem-like property of
cancer stem-like cells in HNSCC and may be a hopeful targeting drug in cancer therapy.
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Introduction
Head and neck squamous cell carcinoma is the six most common
cancer in the world [1], with ~600,000 patients newly diagnosed
each year. Despite advances in the diagnosis and treatment of
cancer, overall survival rates have not improved over the past few
decades. Mortality in patients with HNSCC remains high because of
regional and distant metastases and emergence of local and regional
recurrences [2]. Platinum-based chemotherapy combined with radia-
tion and/or surgery is the standard treatment for local regional recur-
rences or metastatic disease. Currently, only around 35% of patients
show response to this type of therapy and the response is usually
short in duration, lasting 6–9 months [2, 3]. In random clinical trials,
combination therapy is associated with greater toxicity and with no
obvious increment in overall survival [4]. A large meta-analysis of
individual patient data has also reported that concurrent chemother-
apy is not always associated with an improvement in overall survival
in some patients [5]. It has been found that one of the major causes
of failure in HNSCC treatment is the enrichment of CSCs that are
resistant to many current cancer treatments, including chemotherapy
and radiotherapy [6].
In HNSCC, like many epithelial tumours, there is a subpopulation
of cells with cancer stem-like cell properties, purported CSCs. It has
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been found that the multiple stem cell-related molecules are highly
expressed in the HNSCC CSCs, including CD44 [7], CD133 [8], CD49f
[9], ABCG2 [10], Oct4 and Nanog [11]. These CSCs have increasing
self-renewal and tumour formation abilities; they are more inclined to
be locally invasive, metastasis and be resistant to multiple traditional
chemotherapy drugs, which lead to clinical chemotherapy failure,
tumour local recurrence and distant metastasis [12]. It has been sug-
gested that in cases where chemotherapy or radiation treatment fails
to completely eradicate the disease, the residual cancer cells will be
highly enriched for cells that persist in a CSC state [13]. Thus, these
considerations indicate that to be effective in the long-term, success-
ful cancer therapies need to include anti-cancer agents that take effect
on CSCs to prevent the re-growth of cancer cell populations.
As a traditional Chinese medicine, gamboge is an effective as an
anti-inflammatory agent, detoxication, coagulant and a strong apopto-
tic inducer in many types of cancer cells. Gambogic acid (GA) is the
major active compound of gamboge [14]. Gambogic acid has signifi-
cant anti-tumourigenic characteristics and induces apoptosis of differ-
ent types of cancer [15–19]. Recent studies show that GA has great
potential as an anti-cancer compound compared with conventional
chemotherapeutical drugs because GA has shown to be highly selec-
tive in targeting cancer cells [20]. This attribute increased attention
towards GA; however, clinical limitations exist because GA half-life is
very short [21, 22] and presented overt toxicity during a phase II clini-
cal trial. Many efforts have been made to enhance GA anti-tumorigenic
effects, extend drug half-life and lower toxicity. In this study, our labo-
ratory has identified a new gamboge derivative called Compound2
(C2; MW 633), which has a significantly longer half-life of 6 hrs and is
more effective on cancer cells (Fig. S1). Importantly, different from
the traditional chemotherapeutical drug cisplatin (CDDP), C2 effec-
tively inhibits both CSCs and non-CSCs derived from HNSCC.
Materials and methods
Cell lines, cell cultures and reagents
Human HNSCC cell line Cal27 was obtained from American Type Culture
Collection (Manassas, VA, USA); HN13, HN6, HN4, SCC25 were gifts from
University of Maryland School of Dentistry; KB (ATCC CCL-17) and KB/Vin-
cristine (VCR) were obtained from the Cell Bank of the Chinese Academy
of Sciences Type Culture Collection Committee (Shanghai, China). All cell
lines were cultured in DMEM (Gibco, Grand Island, NY, USA) containing
10% foetal bovine serum (FBS, Gibco), 1% glutamine and 1% penicillin-
streptomycin at 37°C in a humidified atmosphere with 5% CO2. Compound
2 was synthesized in WuXi AppTec Co. Ltd (Shanghai, China), and its pur-
ity was 99.8% as testing with thing layer chromatography/high-perfor-
mance liquid chromatography. Stock solution of C2 was prepared as
50 mmol/l in dimethyl sulfoxide (DMSO) and stored at 20°C.
MTT assay
Cells were seeded in 96-wells plates at a density of 3 9 103/well. After
24 h, cells were then treated with serial dilutions of C2 and GA, includ-
ing a negative control with 2& DMSO. After an incubation period of
72 hrs, cell growth was determined with (3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide) (MTT) assay. The optical density value
was measured at 490 and 630 nm as reference with an ELISA plate
reader. The 50% inhibitory concentration (IC50) of C2 and GA was cal-
culated with GraphPad5 software (Version 5.01, GraphPad Software,
Inc., La Jolla, CA, USA).
Western blot
Total proteins were collected in lysis buffer (1% Nonidet P-40, 5%
sodium deoxycholate, 1 mM phenylmethanesulfonyl fluoride, 100 mM
sodium orthovanadate) with protease inhibitor cocktail (Sigma-Aldrich,
St. Louis, MO, USA) and stored at 20°C. Protein concentrations were
determined by using the bovine serum albumin Protein Assay Kit
(Pierce, Rockford, IL, USA). Twenty microgram of total proteins was
separated on 8% SDS-PAGE and then transferred onto polyvinylidene
difluoride membranes (Amersham Pharmacia Biotech, Piscataway, NJ,
USA). After blocking with 5% non-fat milk, the membranes were then
incubated with primary antibodies at 4°C overnight, which included: b-
actin (1:10000 dilution, Sigma-Aldrich); CD133 (1:1000 dilution,
PROTEINTECH, Chicago, IL, USA); CD49f (1:1000 dilution, Abcam, Cam-
bridge, UK); CD44 (1:1000 dilution, EPITOMICS, Burlingame, CA, USA);
Caspase3 (1:1000 dilution, Cell signaling, Danvers, MA, USA); PARP
(1:1000 dilution, Cell signaling); Bcl-2 (1:1000 dilution, Cell signaling),
phospho-AKT(Thr308) (1:1000 dilution, Cell Signaling), AKT (1:1000
dilution, Cell Signaling), Phospho-Erk1/2 (Thr202/Tyr204) (1:1000 dilu-
tion, Cell Signaling), Erk1/2 (1:1000 dilution, Cell Signaling), phospho-
EGFR (Try1068) (1:1000 dilution, Cell Signaling) and EGFR (1:1000
dilution, Cell Signaling). Secondary antibodies goat anti-mouse or goat
anti-rabbit (1:15000 dilutions, LI-COR Biotechnology, Lincoln, NE, USA)
were used for 1 hr at room temperature. Finally, the membranes were
scanned and analysed with the Odyssey Infrared Imaging System
(LI-COR Biosciences).
Real-time PCR
Cells were harvested at 24 or 48 hrs after treatment. Total RNA was
extracted by using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) and
converted to cDNA by using TaKaRa cDNA synthesis kit (TaKaRa,
Dalian, China). Real-time PCR reactions were performed with the SYBR
Premix Ex TaqTM reagents kit (Takara). The primer sequences included
CD44: sense 5′-TAACCGTGATGGCACCCGCT-3′ and anti-sense 5′-TTGAA-
GACGTACTGGTAGCAGGGA-3′; CD133: sense 5′-GCATGCAAAAGCCATCA-
TAG-3′ anti-sense 5′-GGGAATGCCTACATCTGGAA-3′; Oct-4: sense 5′-
CGCACCACTGGCATTG TCAT-3′ anti-sense 5′-TTCTCCTTGATGTCACGCAC-
3′; ABCG2: sense 5′-CTGAGATCCTGAGCCTTTGG-3′ anti-sense 5′-
TGCCCATCACAAC ATCATCT-3′; Nanog: sense 5′-AATACCTCAGCCTCCAGC-
AGATG-3′ anti-sense 5′-CTGCGTCACACCATTGCTATTCT-3′; b-actin: sense
5′-CCTGGCACCCAGCACAAT-3′ anti-sense 5′-GGGCCGGACTCGTCATACT-3′.
Results of real-time PCR were represented as DDCt values and normalized
with the Ct of b-actin. A P-value under 0.05 was defined as significance.
Cell apoptosis analysis
All cells were harvested at 24 hrs after drug treatment or DMSO treat-
ment, stained with Annexin V- PI Apoptosis Detection Kit (BD Bioscienc-
2 ª 2013 The Authors.
Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
es, San Jose, CA, USA) and then analysed on FACSCalibur (BD Bio-
sciences), according to the manufacturer’s protocols.
Rhodamine 123 cell staining
Cells were seeded on slides in 24 well plates. After being treated with
C2 for 24 hrs, cells were incubated at 37°C with 200 ll/well Rh123
(1:1000 dilutions) for 2 hrs, fixed with 4% para-formaldehyde for
10 min., stained with polyvinylidene difluoride for 5 min., and then
mounted on microscopic glasses with 70% glycerol. The slides were
observed with a Leica TCS SP2 confocal spectral microscope (Buffalo
Grove, IL, USA) and three different random fields were observed at
2009 magnification.
Colony formation and anchorage-independent
growth in soft agar
Cal27 were plated at 2000 cells in 6 cm plates and treated with or with-
out C2. Ten days later, the plates were stained with Coomassie Brilliant
Blue dye for 30 min. and washed with PBS. For the soft agar assay, the
bottom agar consisted of 1.2% low melting agarose with DMEM and
10% FBS. The top agar was made from 2000 cells mixed with 1.5 ml
of 0.7% agar with DMEM and 10% FBS. 0.5 ml DMEM was added on
top of the solidified agar layers, where the colonies were allowed to
grow for 2 weeks.
Sphere formation assay
Tumour sphere assay was performed as previously described. Cells
were seeded in a low-adhesion 10-cm plate at a density of 5000 cells.
Spheres were grown in DMEM medium (Gibco) supplemented with
20 ng/ml human EGF and 15 ng/ml human bFGF. EGF and bFGF were
replenished every 3 days. Spheres were counted and photographed
after 14 days.
Flow cytometry analysis
Cells were resuspended in PBS at the concentration of 2 9 107/ml. The
cell suspensions were stained with anti-CD133 (1:1000 dilution, PRO-
TEINTECH), anti-CD49f (1:1000 dilution, Abcam, Cambridge, UK), or is-
otype control on ice for 30 min. in the dark, centrifuged at 300 9 g for
5 min., added the appropriate FITC-labelled second antibody at 1:100
dilution and incubated for another 15 min. on ice in the dark. Analysis
was performed on FACSCalibur (BD Biosciences, San Jose, CA, USA)
flow cytometry.
Isolation of CD133 positive cells
1 9 108 cells were collected and resuspended in 300 ll binding buffer
with 100 ll Fc receptor blocking reagent and 100 ll CD133 microbeads
at 4°C for 30 min. (Miltenyi Biotech, Aubum, CA, USA). The samples
were then loaded on MS columns (Miltenyi Biotech) and CD133 and
CD133+ cells were separated with MACS Cell Separation (Miltenyi Bio-
tech).
Tumour-transplanted model and in vivo
treatment
In vivo experiments were performed in accordance with the institutional
guidelines for the use of laboratory animals. Four-week-old BALB/C
nude female mice were supplied by the Shanghai Experimental Animal
Center, Chinese Academy of Sciences, Shanghai, China. Cal27 cells in
the exponential phase were trypsinized, washed with DMEM and sus-
pended in PBS to obtain a concentration of 1 9 107. Subsequently,
200 ll of suspended cells was subcutaneously inoculated into flanks of
each nude mouse bilaterally. The mice were randomly divided into five
groups, consisting of three mice in each group. The first group served
as negative controls, receiving no treatment. The second group, C2
50 mg/kg group, received oral administration of 50 mg/kg C2 per day.
The third group, C2 100 mg/kg group, received oral administration of
100 mg/kg C2 per day. The fourth group, CDDP group, was treated with
intraperitoneal injections of 5 mg/kg CDDP every other day. The fifth
group, Lap group, received oral administration of 100 mg/kg lapatinib
every other day. Every other day, mice were weighed and the volumes
of the tumours were measured. Treatment was initiated when the
majority of the tumours had reached a volume of 20 mm3 on the 7th
day. Thirty days after drug therapy administration, mice were killed
and the tumours were excised, fixed with 10% formalin and paraffin-
embedded.
Immunohistochemical staining
The paraffin blocks of xenograft tumours were cut into 5 lm sections
for standard immunohistochemical staining (IHC). After heat-induced
antigen retrieval in citric acid buffer (pH 7.0) for 18 min. and blocked in
H2O2 solution for 15 min., slides were then incubated with rabbit anti-
Ki-67, rabbit anti- CD49f, rabbit anti- CD133, rabbit anti-phospho-EGFR
(Tyr1068) at a dilution of 1:100 at 4° overnight. Bound antibody was
detected by a Super Sensitive IHC Detection System (BioGenex, Fre-
mont, CA, USA). The sections were visualized by using diaminobenzi-
dine tetrahydrochloride (Sigma-Aldrich) solution and counter stained
with Harris haematoxylin. Staining was then scored by an experienced
pathologist blinded to the treatment groups.
Results
Compound 2 effectively inhibited the growth of
cancer cells and induced apoptosis, while
exerted only marginal effect on normal cells
To study the effect of C2 on cancer cells, we first examined the viabil-
ity of seven cancer cells treated with gradient dosages of C2 for
72 hrs with MTT assay. As shown in Figure 1A, the inhibitory efficacy
of C2 on cancer cells was more successful compared with the tradi-
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tional chemotherapeutic drug CDDP. The IC50 of C2 on different can-
cer cells was from 0.144 lM (HN4) to 0.885 lM (HN13), with med-
ian value 0.59 lM, while the IC50 of CDDP was from 3.065 lM (Cal
27) to 4.881 lM (KB/VCR), with median value 3.839 lM (Table S1).
Some cancer cells showed less sensitive to C2, while others were
more sensitive, indicating selective effects of C2 on different cells,
while the IC50 of CDDP was more consistent across all cancer cell
lines. We also examined the toxicity of C2 on various primary cultured
normal cells, including periodontal cells, umbilical vein endothelial
cells, and oral mucosa cells. As Figure 1B shows, the IC50 of C2 on
normal cells was from 1.212 to 3.345 lM, with median 1.98 lM,
which was about three times higher than the IC50 of C2 on cancer
cells.
Annexin-V/PI double staining showed that treatment with C2 for
24 hrs induced eminent apoptosis of HNSCC cells, as Figure 2A
shows that the apoptotic rate was 58.1% in Cal27 treated with
0.8 lM C2, compared with 11.5% in cells treated with DMSO. Rh123
cell staining demonstrated that 24-hr treatment with C2 significantly
reduced the mitochondrial membrane potential. Figure 2B shows that
the mitochondrial membrane potential was significantly reduced in
Cal27 treated with 0.4 lM C2. We further examined the expression of
full length Caspase 3, PARP and Bcl-2 in HNSCC cells treated with C2.
As Figure 2C shows, full length of PARP and full length of Caspase3
were decreased in a dose-dependent manner. Bcl-2 was also
decreased in C2-treated Cal27 cells in a dose-dependent manner. The
expression levels of apoptosis-related proteins tested by western blot
supported that C2 induced apoptosis of HNSCC cells.
Compound 2 inhibited colony formation ability
and anchorage-independent growth of cancer
cells
As the efficacy of colony formation and anchorage-independent
growth primarily reflected the self-renewal ability of cancer cells
in vitro, we tested the influence of C2 on these abilities in sev-
eral HNSCC cell lines, including Cal27, KB, and KB/VCR cells. We
found that C2 significantly reduced the colony formation ability
of these HNSCC cells in a dose-dependent manner (Fig. 3A). The
soft agar assay confirmed the inhibitory efficacy of C2 on the
A
B
Fig. 1 Inhibitory effects of C2 on head and neck squamous cell carcinoma (HNSCC) cells. (A) The 50% inhibitory concentration (IC50) of C2 and
CDDP on different HNSCCs. (B) The inhibitory effects of C2 on normal cells (from left to right: periodontal cells, umbilical vein endothelial cells and
oral mucosa cells).
4 ª 2013 The Authors.
Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
self-renewal ability of cancer cells (Fig. 3B). Interestingly, as
Figure 3B shows, C2 exerted similar inhibitory effect on the
anchorage-independent growth of both drug-resistant KB/VCR and
drug-sensitive KB cells.
Compound 2 effectively exerted inhibitory effects
on HNSCC CSCs
As chemo-resistance is a typical feature of HNSCC CSCs and our
former results showed that C2 treatment resulted in a reduction in
colony-forming efficiency of both drug-resistant and -sensitive
HNSCC cancer cells, we further investigated the inhibitory efficacy
of C2 on HNSCC CSCs. Firstly, we examined the influence of C2
on the sphere formation ability of Cal27 cells in serum-free med-
ium, as surrogate readout of stem-cell abundance. Consistently,
we found that C2 significantly inhibited the sphere formation abil-
ity of Cal27 cells, while traditional chemotherapeutic drug CDDP
had no obvious inhibition effect (Fig. 4A). Then, we investigated
whether treatment with C2 influenced the expression of stem cell-
related molecules in cancer cells. As Figure 4B shows, after 24-hr
treatment with CDDP, most tested stem cell-related molecules,
including CD44, CD133, CD49f and Nanog were significantly up-
regulated in CDDP-treated group, but no such increases were
observed in C2-treated group. On the contrary, the mRNA levels
of CD133 and CD49f were remarkably reduced in C2-treated
group. Western blot confirmed that C2 inhibited the expression of
CD49f and CD133 in a dose-dependent manner in Cal27 cells,
while CDDP somehow increased the expression of CD49f and
CD133 in Cal27 cells (Fig. 4C). Flow cytometry analysis further
revealed that 0.4-lM C2 treatment for 48 hrs suppressed these
CD49f+ and CD133+ subpopulations in Cal27 cells, while 2.5 lg/ml
A
B
C
Fig. 2 C2 induced apoptosis of cancer cells. (A) Annexin-V/PI double staining shows that treatment with 0.8 lM C2 for 24 hrs, induced apoptosis in
58.1% of Cal27 cells compared with only 11.5% in DMSO-treated group. (B) Treatment with 0.4 lM C2 significantly reduced the mitochondrial
membrane potential of Cal27 cells. (C) The expression of full length PARP, full length Caspase3 and Bcl-2 were remarkably decreased in a drug con-
centration-dependent manner. Error bars represent SD. * indicates P < 0.05.
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CDDP treatments for 48 hrs significantly augmented these sub-
populations from 7.50% to 46.15% (Fig. 4D). As CD133 is a com-
monly used CSC marker in various types of cancer, we then
isolated CD133+ and CD133 subpopulations from Cal27 and KB/
VCR cells (Fig. 4E) and compared their sensitivity with C2 treat-
ment. As Figure 4F and Table S2 show, there are no significant
differences between the IC50 of C2 in CD133
+ cells and the IC50
of C2 in CD133 cells. However, CD133 cells were increasingly
more sensitive to CDDP compared with CD133+ cells derived from
both Cal27 and KB/VCR. Therefore, compared with conventional
chemotherapeutic CDDP regimen, C2 exhibited a significantly
increased effective inhibitory effect on HNSCC CSCs.
Compound 2 exerted inhibitory effect on HNSCC
in vitro via repressing the activation of EGFR
pathway
As increasing amounts of data demonstrate that the activation of
EGFR pathway plays an indispensible role in the maintenance
and proliferation of stem cells by regulating the expression of
multiple stem cell-related molecules [23], we investigated the
effect of C2 on the activation of EGFR pathway. Binding of EGFR
to its ligands EGF leads to autophosphorylation of tyrosine
residues on the EGFR and subsequent activation of signal trans-
duction pathways that involved in regulating cellular proliferation,
differentiation and survival. Phosphorylation of Akt and Erk are
two most widely studied transduction molecules triggered by
activation of EGFR; while in our study, as Figure 5A shows, after
24-hr treatment with C2, the stimulation effect of EGF on EGFR
phosphorylation and the activation of EGFR downstream Akt
were significantly inhibited by C2 in a dose-dependent manner,
while after 48-hr treatment with C2, the EGF induced up-regula-
tion of stem cell-related molecules, including CD49f, CD133
and CD44 were significantly blocked (Fig. 5C). Similar results
were observed in lapatinib-treated cells, which is a small
molecule inhibitor of EGFR tyrosine-kinases. Consistently, CDDP
treatment failed to inhibit the stimulation of EGF on EGFR signal-
ling and resulted in the up-regulation of CD49f, CD133 and
CD44.
A
B
Fig. 3 C2 significantly inhibited colony formation ability and anchorage-independent growth of cancer cells. (A) C2 inhibited the colony formation
ability of Cal27 cells. (B) C2 consistently inhibited the anchorage-independent growth in soft agar of both drug-sensitive KB cells and drug-resistant
KB/VCR cells, which indicated that C2 might be able to target cancer stem cells. Error bars represent SD. * indicates P < 0.05.
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Compound 2 exerted a significant inhibitory
effect on HNSCC xenograft tumours and
suppressed the EGFR phosphorylation in vivo
To evaluate the in vivo effect of C2 on HNSCC therapy, we used Cal27
cells to establish transplanted tumours in nude mice. When the xeno-
graft tumours averaged 20 mm3 in size, the mice were randomly
divided into five different treatment groups, with three mice assigned
to each group. In the blank control group, the tumour grew very
quickly without any drug treatment and reached more than 500 mm3
at the 30th day after inoculation. In all four treatment groups with
CDDP, C2, or lapatinib, tumour growths were significantly inhibited,
as shown in Figure 6A and B. The inhibitory effect on the implanted
tumours in the C2 100 mg/kg group had the best outcome amongst
all treatment groups, while the tumours generated in both the C2
50 mg/kg group and C2 100 mg/kg group were significantly smaller
in size than tumours generated in CDDP group (P < 0.05, Fig. 6B).
As shown in Figure 6C, during the treatment the mice in C2 50 mg/
kg, C2 100 mg/kg, lapatinib and blank control groups had steadily
gained weight, while mice in CDDP group did not gain weight at all or
slightly lost body weight. Immunohistochemical staining of the
excised transplanted tumours (Fig. 7) further validated that similarity
A
C
E F
D
B
Fig. 4 C2 effectively exerted inhibitory effects on head and neck squamous cell carcinoma cancer stem cells. (A) C2 remarkably suppressed tumour
sphere formation of Cal27 cells in serum-free medium, while CDDP failed to do so. (B) CDDP treatment led to increases in multiple stem cell-related
molecules, including CD44, CD133, CD49f and Nanog, while no such increases were observed in the C2-treated group. On the contrary, the mRNA
levels of CD133 and CD49f were remarkably reduced in C2-treated group. (C) Western blot confirmed that C2 inhibited the expression of CD49f and
CD133 in a dose-dependent manner in Cal27 cells, while CDDP somehow increased their expressions. (D) Flow cytometry analysis revealed that
CD49f+ and CD133+ subpopulations were suppressed by C2 treatment, but were enriched by nearly 50% by CDDP treatment. (E) CD133+ and
CD133 Cal27 and KB/VCR cells were isolated. (F) The sensitivity to C2 treatment was tested. There was no significant difference between the 50%
inhibitory concentration (IC50) of C2 in CD133
+ populations and CD133 populations; however, CD133 cells were much more sensitive to CDDP
compared with CD133+ cells. Error bars represent SD. * indicates P < 0.05.
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to the lapatinib treatment group; C2 effectively inhibited the expres-
sion of Ki-67, phosphor-EGFR, CD49f and CD133 in cancer cells in a
dose-dependent manner, while CDDP failed to exert such inhibitory
effects.
Discussion
Patients with non-treatable advanced recurrent or metastatic HNSCC
have a median survival of 6 months [4]. Combination platinum-based
chemotherapy has been the standard of care, but large meta-analysis
of individual patient data has reported that concurrent chemotherapy
is not associated with an improvement in overall survival in patients
with HNSCC [5]. As shown here and elsewhere [13, 24], treatment
with conventional chemotherapeutics actually imposes a positive
selection for CSC survival and expansion. We found that after CDDP
treatment, HNSCC have an increased proportion of cells with CD133+
and CD49f+ and increased expression of CD44, CD133, CD49f, and
Nanog. This suggests that when chemotherapy fails to completely
eradicate the disease, the residual cancer cells will be enriched for
cells that carry a CSC feature. These observations indicate that cancer
therapies should include agents that can effectively target CSCs.
In this study, we identified gamboge derivative C2, which presents
a hopeful anti-cancer treatment candidate that can be used to target
CSCs. As a promising anti-tumourigenic candidate, C2 has a pro-
longed half-life and with greatly enhanced tumour inhibitory effects,
while having mild toxicity to normal cells and can be orally adminis-
trated. In vivo, the anti-tumourigenic effects of C2 were eminent and
A
B
Fig. 5 C2 exerted inhibitory effect on head and neck squamous cell carcinoma (HNSCC) in vitro via repressing the activation of EGFR pathway. (A)
As EGFR kinase can promote acquisition of cancer stem-cell (CSC) properties in HNSCC and studies have also found overexpression of EGFR
resulted in an increased expression of multiple stem-cell marker, so we compared the influence of C2 and CDDP on the activation of EGFR signalling
pathway. Small molecular inhibitor of EGFR lapatinib was used as a positive control. Western blot analysis revealed that after 24-hr treatment with
C2, the stimulation effect of EGF on the EGFR phosphorylation and the activation of EGFR downstream AKT were significantly inhibited by C2 in a
dose-dependent manner, while CDDP failed to do so, and lapatinib also significantly inhibited the EGF phosphorylation and the activation of AKT
induced by EGF. (B) Western blot analysis showed that EGF treatment significantly induced the up-regulation of multiple stem cell-related molecules
in cancer cells; while in C2 treatment and lapatinib treatment groups, the EGF induced up-regulation of stem cell-related molecules were all blocked;
yet, no such inhibition has been observed in CDDP treatment group. The data indicate that the efficacy of C2 on CSCs is largely through its inhibi-
tory effect on EGF/EGFR signal pathway, resulting in loss of expression of multiple CSC markers in HNSCC. The relative quantities of each blot were
normalized to the value of b-actin and listed in the Tables.
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the inhibition efficacy of oral administration of 50 mg/kg C2 or
100 mg/kg C2 alone was vastly improved compared with that of the
peritoneal administration of 5 mg/kg CDDP. At the same time, there
was no obvious adverse effect of C2 on the weight gain of those treat-
ment groups, unlike the CDDP treatment group experienced. It is of
note that the inhibitory effect of C2 on drug-resistant KB/VCR cells
was very close to on the drug-sensitive KB cells, while the normal
cells were insensitive to C2 treatment, which made C2 an attractive
cancer selective drug. Our further investigation revealed that different
from CDDP treatment, the C2 treatment effectively inhibited the
expression of multiple stem cell-related molecules, suppressed col-
ony formation efficiency and decreased the anchorage-independent
growth in soft agar and sphere-forming ability. CD133 is a widely
used CSC marker [25, 26]. Compared with CD133 HNSCC cells,
CD133+ CSC-like cells are more resistant to CDDP treatment, while
we found that C2 effectively inhibited the growth of both CD133+ and
CD133 HNSCC cells. These observations indicate that C2 is different
from conventional chemotherapeutic drugs and treatment with C2 will
not lead to selectively enrich cancer cells with CSC features. The
in vivo treatment with C2 or CDDP on transplanted animal models
further confirmed these observations as only C2 treatment effectively
suppressed the expression of multiple CSC-related molecules both
in vivo and in vitro.
The transmembrane protein, EGFR, has an intrinsic tyrosine
kinase activity and regulates cell growth in response to binding of
ligand like EGF [27]. This pathway is a potent regulator of tumour
cell growth, invasion, angiogenesis and metastasis. It is overexpres-
sed in almost all HNSCC tumours and its overexpression is associ-
ated with poor prognosis [28]. A recent study indicated that EGFR
kinase promoted acquisition of CSC properties in HNSCC. Overex-
pression of EGFR resulted in an increased expression of stem-cell
marker, CD44, Oct-4, and Nanog [29], so EGFR inhibition might be
an effective method to target the CSC populations in HNSCC. It has
been reported that small molecule inhibitors of EGFR, such as lapati-
nib, erlotinib, gefitinib and cetuximab, can prevent the growth and
progression of HNSCC and decrease the expression of stem cell-
related molecule. Cetuximab has recently been approved for HNSCC
treatment [30]. Here, we found that treatment with C2 for 24 hrs
A
B C
Fig. 6 Inhibitory effects of C2 on Cal27-derived xenografted tumours. (A) Oral administration of C2 effectively inhibited the tumour growth in vivo.
The inhibitory effect of C2 100 mg/kg treatment was the strongest positive compared with other treatment groups. (B) The tumour growth curve of
each treatment group. * indicates significant difference between control group and treated group. ** indicates significant difference between CDDP
group and C2 50 mg/kg group. *** indicates significant difference between CDDP group and C2 100 mg/kg group. (C) The weight changes of each
different treatment group. The CDDP treatment group significantly lost overall body weight, while there were no remarkable body weight changes in
the other treatment groups. Error bars represent SD. * indicates P < 0.05.
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can effectively block the stimulation effects of EGF on HNSCC cells
in a dose-dependent manner. In C2-treated cells, EGF fails to initiate
the phosphorylation of EGFR, resulting in significantly decreased
expression of phosphory-Akt and slightly decreased expression of
phosphory-Erk1/2. Also, 48 hrs after C2 treatment, similar to the la-
patinib treatment, multiple stem cell-related molecules, such as
CD133, CD49f and CD44 were down-regulated; yet, no such inhibi-
tion has been observed in CDDP treatment group. This observation
demonstrates that the efficacy of C2 on CSCs is largely through its
inhibitory effect on EGF/EGFR signal pathway and C2 not only effec-
tively inhibited the in vivo growth of transplanted HNSCC but also
blocked the activation of EGFR signal and resulted in loss of expres-
sion of multiple CSC markers in HNSCC. C2 may be a useful adju-
vant to current chemotherapeutic drug.
Fig. 7 Haematoxylin and eosin staining and immunohistochemical assay of xenografted tumours. C2 effectively inhibited the expression of Ki-67,
phosphor-EGF, CD49f and CD133 in xenograft tumours in a dose-dependent manner, while CDDP failed to exert such inhibitory effects.
10 ª 2013 The Authors.
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Conclusion
We identified a new Gamboge derivative called C2, which presented
stronger and more effective anti-tumourigenic activity against
HNSCC. Notably, C2 can effectively target both CSCs and non-CSCs
within HNSCC, which makes it different from conventional chemo-
therapeutic drugs, in that it prevents the selective enrichment of
CSCs after chemotherapeutic drug treatment. The inhibitory effect of
C2 on CSCs largely occurs through blocking the activation of EGF/
EGFR signal pathway, which leads to down-regulation of multiple
stem cell-related molecules. These features make C2 a promising
candidate for use in long-term and recurrent cancer drug therapies.
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